Nanosuspension formulation to improve the dissolution rate of Clonazepam

Many FDA approved drugs currently available in the market have limitations in crossing the blood brain barrier (BBB) owing to its complicated vasculature posed by the presence of specialized cells One of the most challenging problems, if not the most challenging, in drug development is not to develop drugs to treat diseases of the central nervous system (CNS), but to manage to distribute them to the CNS across the blood–brain barrier. The development of BBB targeting technologies is a very active field of research and development. One goal is to develop chemically modified derivatives of CNS drug (clonazepam) chemically modified nanoparticulate of drugs, capable of crossing biological barriers, in particular the BBB. Nanocarrier drug delivery involves targeting CNS drugs enclosed in a particular PVP polymer. Drug nanoparticles have been shown to improve bioavailability and enhance drug exposure for oral and parenteral dosage forms. Nanoparticles of clonazepam were prepared by many methods.